| HOME >> BIOLOGY >> TECHNOLOGY |
Amortiza-
tion of
intangible
assets 1,913,040 1,269,158 137,760 3,319,958
Impairment
of
intangible
assets 1,829,538 - - 1,829,538
Loss on
sale of
marketable
securities - 2,623 14,881 1,191,329
Stock-based
compensa-
tion 1,716,913 2,588,413 1,278,955 6,153,476
Stock-based
consider-
ation - 100,000 192,750 292,750
Warrants-
based
consider-
ation - 54,775 - 54,775
Change in
non-cash
operating
working
capital:
Accounts
receivable
and
prepaid
expenses 1,816,092 (672,639) (367,916) 311,701
Accounts
payable
and accrued
liabilities
and
deferred
revenue 11,604,460 (1,599,032) 2,396,216 13,663,354
-------------------------------------------------------------------------
(12,743,090) (24,010,292) (12,194,932) (90,250,938)
Financing
activities:
Repayment of
debentures - - (1,469,425) (1,469,425)
Issuance of
common shares
on exercise
of options 11,232 851,322 109,318 2,516,246
Issuance of
common shares
on exercise
of warrants 89,375 3,627,430 432,402 4,371,555
Redemption of
preferred
shares - - - (2,630,372)
Pu
'/>"/>
| SOURCE YM BioSciences Inc. Copyright©2007 PR Newswire. All rights reserved |